Mineralys Therapeutics (NASDAQ:MLYS) Price Target Cut to $24.00 by Analysts at The Goldman Sachs Group
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its price objective reduced by research analysts at The Goldman Sachs Group from $28.00 to $24.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective suggests a potential upside of […]
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its price objective reduced by research analysts at The Goldman Sachs Group from $28.00 to $24.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective suggests a potential upside of […]
